Organization (Industry)
PALATIN TECHNOLOGIES INC
ClinicalTrials.gov lists PALATIN TECHNOLOGIES INC as lead sponsor of 11 trials. It has 9 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PALATIN TECHNOLOGIES INC: 11 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dry Eye Syndromes | 2 |
| Asthma | 1 |
| Colitis, Ulcerative | 1 |
| Heart Failure | 1 |
| Hypertension | 1 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2015 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2008 | 1 |
| 2006 | 1 |
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PL9643 Ophthalmic Solution | Dry Eye Syndromes | Phase 3 | 1 |
| Vehicle Ophthalmic Solution | Dry Eye Syndromes | Phase 3 | 1 |
| TIRZEPATIDE | Obesity | Phase 2 | 1 |
| PL8177 | Inflammatory Bowel Diseases | Phase 2 | 1 |
| Bremelanotide | Obesity | Phase 2 | 1 |
Showing 5 of 9 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Bremelanotide | 6 |
| TIRZEPATIDE | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 0% on time (n=5) |
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of patient-reported outcomes | 2 |
| Journal of women's health (2002) | 2 |
| Obstetrics and gynecology | 2 |
| Clinical therapeutics | 1 |
| Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics | 1 |
Showing 5 of 8 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 67 | 3 | 2025-11-04 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 0 | -17,307,349 | 14,898,494 |
| 2024 | 4,490,090 | -29,736,113 | 22,400,372 |
| 2023 | 4,853,678 | -24,036,741 | 22,630,577 |
| 2022 | 1,468,457 | -36,198,299 | 21,327,434 |
| 2021 | -188,597 | -33,596,495 | 12,926,559 |
| 2020 | 117,989 | -22,426,023 | 13,959,397 |
| 2019 | 60,300,476 | 35,773,027 | 14,857,095 |
| 2018 | 67,134,758 | 24,702,714 | 32,566,217 |
| 2017 | 67,134,758 | 24,702,714 | 32,566,217 |
| 2016 | 0 | -51,712,936 | 43,071,051 |
Showing 10 of 11 fiscal years.
Financing and grant events (37)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-12 | Other financing | not disclosed | Edgar offerings |
| 2025-11-12 | Public offering | not disclosed | Sec extracted |
| 2025-11-12 | Public offering | 2,370,000 | Sec extracted |
| 2025-11-10 | Other financing | not disclosed | Edgar offerings |
| 2025-11-05 | Public offering | not disclosed | Sec extracted |
Showing 5 of 37 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (116)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-12 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-12 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-12 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-10 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-05 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 116 events.
Biomarker capability evidence (29)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AOC1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| AOC1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| DAO | Trial sponsor | Primary endpoint in a Phase 3 trial |
| DAO | Trial sponsor | Primary endpoint in a Phase 3 trial |
Showing 5 of 29 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.